Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMBA Study: MB09 versus Prolia in postmenopausal osteoporosis
2021-003609-24Phase 3Completed
- Sponsor
- mAbxience
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by mAbxience. Primary endpoint: Percentage change from baseline in lumbar spine BMD at Month 12. Started Nov 2021; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2021-003609-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003609-24.